Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573079 | 0.88 | ALDH1A1 (0.46) | SRCPTPN1FDPSALDH1A1MAPK1 | |
| SCHEMBL7139014 | 0.88 | SRC (0.42) | SRCPTPN1FDPSALDH1A1MAPK1 | |
| SCHEMBL4990719 | 0.84 | SRC (0.46) | SRCFDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13116218 | 0.84 | SRC (0.42) | SRCFDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL347037 | 0.83 | SRC (0.51) | SRCFDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL5351709 | 0.82 | SRC (0.53) | SRCFDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4137984 | 0.81 | FDPS (0.43) | PTPN1FDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2010378 | 0.80 | SRC (0.52) | SRCALDH1A1L3MBTL1TDP1MAPT | |
| SCHEMBL4990709 | 0.80 | SRC (0.41) | SRCFDPSALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL13554474 | 0.79 | ALDH1A1 (0.50) | FDPSALDH1A1MAPK1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504685-A | Benzopyran flavonoid compound, preparation method and application thereof, and pharmaceutical preparation | 南开大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| CN-107252429-A | New antiinflammatory | 雷斯韦洛吉克斯公司 | 2017-10-17 | — | — | CN | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011075210-A2 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
| EP-0590793-B1 | Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0595546-B1 | Benzylidene derivatives | SHIONOGI & CO (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5436257-A | Low toxicity | SANKYO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5418230-A | Antiinflammatory | SHIONOGI & CO., LTD. (JP) | 1995-05-23 | — | — | US | disclosed |
| EP-0595546-A1 | Benzylidene derivatives | SHIONOGI & CO., LTD. (JP) | 1994-05-04 | — | — | EP | disclosed |
| EP-0590793-A1 | Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SRC 3607/4885PTPN1 1889/4885FDPS 2215/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SRC 3607/4885PTPN1 1889/4885FDPS 2215/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SRC 3607/4885PTPN1 1889/4885FDPS 2215/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | SRC 3607/4885PTPN1 1889/4885FDPS 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.